Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04322708
Registration number
NCT04322708
Ethics application status
Date submitted
24/03/2020
Date registered
26/03/2020
Date last updated
2/01/2024
Titles & IDs
Public title
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
Query!
Scientific title
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis
Query!
Secondary ID [1]
0
0
AK002-014
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
KRYPTOS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Eosinophilic Esophagitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Allergies
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Placebo
Treatment: Drugs - lirentelimab (AK002)
Placebo Comparator: Placebo - Subjects in this arm will receive 6 monthly doses of placebo.
Experimental: 1 mg/kg of lirentelimab (AK002) - Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) (1mg/kg).
Experimental: 3 mg/kg of lirentelimab (AK002) - Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002): A first dose of 1 mg/kg, followed by 5 monthly doses of 3 mg/kg.
Other interventions: Placebo
Placebo
Treatment: Drugs: lirentelimab (AK002)
Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Subjects Who Achieve a Peak Esophageal Intraepithelial Count of =6 Eosinophils/Hpf at Week 24
Query!
Assessment method [1]
0
0
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies.
Query!
Timepoint [1]
0
0
At Week 24
Query!
Primary outcome [2]
0
0
Change in Dysphagia Symptom Questionnaire (DSQ) Score From Baseline to Weeks 23-24.
Query!
Assessment method [2]
0
0
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Query!
Timepoint [2]
0
0
Baseline to Weeks 23-24
Query!
Secondary outcome [1]
0
0
Percent Change in Peak Esophageal Intraepithelial Eosinophil Count From Baseline to Week 24
Query!
Assessment method [1]
0
0
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies. A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.
Query!
Timepoint [1]
0
0
Baseline to Week 24
Query!
Secondary outcome [2]
0
0
Subjects Achieving Peak Esophageal Intraepithelial Eosinophil Count of =1 Eosinophil/Hpf at Week 24
Query!
Assessment method [2]
0
0
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies.
Query!
Timepoint [2]
0
0
At Week 24
Query!
Secondary outcome [3]
0
0
Subjects Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/Hpf at Week 24
Query!
Assessment method [3]
0
0
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies.
Query!
Timepoint [3]
0
0
At Week 24
Query!
Secondary outcome [4]
0
0
Number of Treatment Responders
Query!
Assessment method [4]
0
0
Treatment responders defined by >30% improvement in symptoms (DSQ) at Weeks 23-24 and peak intraepithelial eosinophilic count of =6 cells/hpf at Week 24
Query!
Timepoint [4]
0
0
At Weeks 23-24 and Week 24, Respectively
Query!
Secondary outcome [5]
0
0
Subjects Who Achieve >50% Reduction in DSQ Score From Baseline to Weeks 23-24
Query!
Assessment method [5]
0
0
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Query!
Timepoint [5]
0
0
Weeks 23-24
Query!
Secondary outcome [6]
0
0
Percent Change in DSQ Score From Baseline to Weeks 23-24
Query!
Assessment method [6]
0
0
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Query!
Timepoint [6]
0
0
Baseline to Weeks 23-24
Query!
Secondary outcome [7]
0
0
Change in Biweekly Mean DSQ Over Time Using MMRM
Query!
Assessment method [7]
0
0
The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.
Query!
Timepoint [7]
0
0
Baseline to Weeks 23-24
Query!
Secondary outcome [8]
0
0
Change in EoE Reference Score for Endoscopic Abnormalities (EREFS) From Baseline to Week 24
Query!
Assessment method [8]
0
0
EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.
Query!
Timepoint [8]
0
0
Baseline to Week 24
Query!
Eligibility
Key inclusion criteria
Key
1. Male or female aged =12 and =80 years at the time of signing ICF.
2. Confirmed diagnosis of EoE and esophageal intraepithelial eosinophilic infiltration of
=15 eosinophils/hpf in 1 hpf from a biopsy collected during the Screening EGD without
any other cause for the esophageal eosinophilia.
3. History (by patient report) of an average of =2 episodes of dysphagia with intake of
solid foods per week during the 4 weeks prior to Screening.
4. Subjects must have failed or not be adequately controlled on standard of care
treatments for EoE symptoms, which could include PPI, systemic or topical
corticosteroids, and/or diet, among others.
5. If on an allowed treatment for EoE, stable dose for at least 4 weeks prior to
Screening and willingness to continue that dose for the study duration.
6. If patient is on pre-existing dietary restrictions, willingness to maintain dietary
restrictions throughout the study, as much as possible.
7. Able and willing to comply with all study procedures.
8. Female subjects must be either post-menopausal for at least 1 year with FSH level >30
mIU/mL at Screening or surgically sterile (tubal ligation,hysterectomy, or bilateral
oophorectomy) for at least 3 months, or if of childbearing potential, have a negative
pregnancy test and agree to use dual methods of contraception, or abstain from sexual
activity from screening until the end of the study, or for 120 days following the last
dose of study drug, whichever is longer. Male subjects with female partners of
childbearing potential must agree to use a highly effective method of contraception
from Screening until the end of the study or for 120 days following the last dose of
study drug,whichever is longer. All fertile men with female partners of childbearing
potential should be instructed to contact the Investigator immediately if they suspect
their partner might be pregnant at any time during study participation.
Key
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Concomitant EG, EoD, or eosinophilic colitis (EC).
2. EG and/or EoD (=30 eosinophils/hpf in 5 hpf in the stomach and/or =30 eosinophils/hpf
in 3 hpf in the duodenum) as determined by central histology assessment of biopsies
collected during the Screening EGD.
3. Causes of esophageal eosinophilia other than EoE or one the following:
hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, or
peripheral blood absolute eosinophil count of >1500 eosinophils/µL.
4. History of inflammatory bowel disease, celiac disease, achalasia, and/or esophageal
surgery.
5. Any esophageal stricture unable to be passed with a standard diagnostic 9 mm to 10 mm
upper endoscope or any critical esophageal stricture that requires dilation during
screening.
6. History of bleeding disorders or esophageal varices.
7. History of malignancy; except carcinoma in situ, early stage prostate cancer, or
non-melanoma skin cancers. However, cancers that have been in remission for more than
5 years and are considered cured, can be enrolled (with the exception of breast
cancer). All history of malignancy (including diagnosis, dates, and compliance with
cancer screening recommendations) must be documented and certified by the
Investigator, along with the statement that in their clinical judgment the tissue
eosinophilia is attributable to EGID, rather than recurrence of malignancy.
8. Active Helicobacter pylori infection (as determined by central histology staining of
the biopsy collected during the Screening EGD), unless treated and confirmed to be
negative prior to randomization and symptoms remain consistent.
9. Positive Ova and Parasite (O&P) test at Screening, seropositive for Strongyloides
stercoralis at Screening, and/or treatment for a clinically significant helminthic
parasitic infection within 6 months of Screening.
10. Seropositive for HIV or hepatitis at Screening, except for vaccinated patients or
patients with a history of hepatitis that has since resolved.
11. Prior exposure to AK002 or hypersensitivity to any constituent of AK002.
12. Change in dose of inhaled corticosteroids, nasal corticosteroids, PPI, and/or diet
therapy within 4 weeks prior to Screening.
13. Use of oral corticosteroids (swallowed topical or systemic corticosteroids) within 8
weeks prior to Screening.
14. Use of any biologics or medications that may interfere with the study, such as
immunosuppressive or immunomodulatory drugs including azathioprine, JAK inhibitors,
6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, anti-TNF, anti-IL-4
receptor, e.g., dupilumab), anti-IL-5 (e.g., mepolizumab), anti-IL-5 receptor (e.g.,
benralizumab), anti-IL-13 (e.g., lebrikizumab), anti-IgE (e.g., omalizumab), within 12
weeks prior to Screening.
15. Participation in a concurrent interventional study with the last intervention
occurring within 30 days prior to administration of study drug or 90 days or 5
half-lives, whichever is longer, for biologic products.
16. Vaccination with live attenuated vaccines =30 days prior to initiation of treatment in
the study, during the treatment period, or vaccination expected =5 half-lives (=4
months) following study drug administration.
17. Treatment with chemotherapy or radiotherapy in the preceding 6 months.
18. Presence of abnormal laboratory values considered by the Investigator to be clinically
significant.
19. Any disease, condition (medical or surgical), or cardiac abnormality, which in the
opinion of the Investigator, would place the subject at increased risk.
20. Known history of alcohol, drug, or other substance abuse or dependence.
21. Women who are pregnant, breastfeeding, or planning to become pregnant while
participating in the study.
22. Any other reason that in the opinion of the Investigator or Medical Monitor makes the
patient unsuitable for enrollment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2/Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/01/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
277
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
Allakos Investigational Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Allakos Investigational Site - Elizabeth Vale
Query!
Recruitment hospital [3]
0
0
Allakos Investigational Site - Box Hill
Query!
Recruitment hospital [4]
0
0
Allakos Investigational Site - Prahran
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
3181 - Prahran
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Montana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Utah
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
Netherlands
Query!
State/province [30]
0
0
North Holland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Allakos Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to
assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and
adolescent patients with active eosinophilic esophagitis. Subjects who complete the
randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses
of open-label lirentelimab (AK002) through the OLE Period of the study.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04322708
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Craig Paterson, MD
Query!
Address
0
0
Allakos Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04322708
Download to PDF